Publications by authors named "Motovska Zuzana"
Acute myocardial infarction (AMI) and valvular heart disease (VHD) are the leading causes of cardiovascular morbidity and mortality. The epidemiology of VHD has changed in recent decades with an aging population, increasing risk factors for cardiovascular disease and migration, all of which have a significant implifications for healthcare systems. Due to common pathophysiological mechanisms and risk factors, AMI and VHD often coexist.
View Article and Find Full Text PDFCardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze whether ticagrelor is more effective than clopidogrel in reducing heart damage during elective coronary procedures for patients with and without prior clopidogrel treatment.
- Out of 1,882 participants, those who were not on clopidogrel had a lower rate of heart injury compared to those who had been, but overall, ticagrelor did not show significant benefits over clopidogrel for reducing complications.
- The findings suggest that clopidogrel-naive patients generally experienced fewer complications due to a lower risk profile and simpler procedures, with no notable differences in outcomes based on previously taking clopidogrel.
Article Synopsis
- The study aimed to assess the effectiveness of ticagrelor versus clopidogrel in preventing cardiovascular events among chronic coronary syndrome patients undergoing complex percutaneous coronary interventions (PCI).
- Among 1,866 patients in the trial, nearly half were identified as having complex PCI, which was associated with significantly higher rates of myocardial infarction and other complications.
- Despite the increased risk associated with complex PCI, ticagrelor did not demonstrate any advantage over clopidogrel in reducing these adverse events.
Article Synopsis
- - The IAMI trial studied 2571 patients with acute myocardial infarction to assess the impact of influenza vaccination on cardiovascular events, comparing outcomes between early and late season vaccinations over a 12-month period.
- - Results showed no significant difference in the effectiveness of the vaccine whether given early or late, with similar percentages of primary composite endpoints observed in both groups (6% early, 4.7% late for vaccinated participants).
- - Although early vaccination demonstrated a potentially greater effect on overall mortality, the findings were not statistically significant; thus, the study reinforces recommending influenza vaccination for all cardiovascular patients, regardless of timing.
Article Synopsis
- The study aimed to investigate the effects of the timing of P2Y inhibitor administration on myocardial necrosis during elective percutaneous coronary intervention (PCI), utilizing data from the ALPHEUS trial.
- Results revealed that patients who received P2Y inhibitors closer to the PCI procedure had higher rates of myocardial necrosis compared to those who were given the medication earlier, with improved outcomes seen in groups that received longer loading times.
- While the study found a correlation between timing and myocardial injury, it noted that bleeding complications were minimal and did not vary significantly among the different timing groups, leaving long-term clinical effects unclear.
Introduction And Objectives: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and prognosis of patients with CS-STEMI and multivessel coronary disease (MVD) treated with culprit vessel-only pPCI or multivessel-pPCI during the initial procedure.
Material And Methods: From 2016 to 2020, 23,703 primary PCI patients with STEMI were included in a national all-comers registry of cardiovascular interventions.
Background: Sex- and gender-associated differences determine the disease response to treatment.
Aim: The study aimed to explore the hypothesis that progress in the management of STE-myocardial infarction (STEMI) overcomes the worse outcome in women.
Methods And Results: We performed an analysis of three randomized trials enrolling patients treated with primary PCI more than 10 years apart.
Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients.
Eur Heart J Acute Cardiovasc Care
January 2023
Aims: To use quality indicators to study the management of ST-segment elevation myocardial infarction (STEMI) in different regions.
Methods And Results: Prospective cohort study of STEMI within 24 h of symptom onset (11 462 patients, 196 centres, 26 European Society of Cardiology members, and 3 affiliated countries). The median delay between arrival at a percutaneous cardiovascular intervention (PCI) centre and primary PCI was 40 min (interquartile range 20-74) with 65.
Background: Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI.
Methods: A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020.
Impact of admitting department on the management of acute coronary syndrome after an out of hospital cardiac arrest.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
June 2023
Aim: This study aimed to analyze the influence of the hospital admitting department on adherence to the Guidelines of European Society of Cardiology for management of acute coronary syndromes in patients after out-of-hospital cardiac arrest (OHCA) of coronary etiology.
Methods: We studied retrospective-prospective register of 102 consecutive patients with OHCA as a manifestation of acute coronary syndrome (ACS). Patients were admitted to the coronary care unit (CCU) 52, general intensive care unit (GICU) 21, or GICU after initial Cath lab treatment (CAG-GICU) 29.
Cardiogenic shock is a state of reduced cardiac output leading to hypotension, pulmonary congestion, and hypoperfusion of tissues and vital organs. Despite the advances in intensive care over the last years, the morbidity and mortality of patients remain high. The available studies of patients with cardiogenic shock suggest a connection between clinical variables, the level of biomarkers, the results of imaging investigations, strategies of management and the outcome of this group of patients.
View Article and Find Full Text PDFBackground: Intermediate-high risk acute pulmonary embolism (PE) remains associated with substantial mortality despite anticoagulation therapy.
Aims: The aim of this randomised pilot study was to compare catheter-directed thrombolysis to standard anticoagulation therapy.
Methods: Intermediate-high risk acute PE patients were admitted to a tertiary care centre (November 2019 to April 2021) and randomised in a 1:1 ratio to catheter-directed thrombolysis (CDT) or standard anticoagulation.
Many scoring systems for predicting the outcomes of patients with acute coronary syndrome (ACS) have been proposed. In some populations, a significant reduction in length of hospital stay may be achieved without compromising patient prognoses. However, the use of such scoring systems in clinical practice is limited.
View Article and Find Full Text PDFManaging patients with acute coronary syndrome (ACS) in an ageing population with comorbidities is clinically and economically challenging. Well-conducted unselected registries are essential for providing information on real-day clinical practice. The aim was to create a long term, very detail-controlled registry of unselected patients admitted with ACS to a high-volume centre in Central Europe.
View Article and Find Full Text PDFObjectives: Based on previous studies with clopidogrel, the time between acute myocardial infarction (AMI) symptoms onset and primary percutaneous coronary intervention (PCI) was proven as important prognostic factor. Our aim was to assess the relationship between symptoms onset to needle time (SNT) and procedural results and the occurrence of ischemic endpoints in primary angioplasty patients treated with potent P2Y12 inhibitors.
Methods: A total of 1,131 out of 1,230 patients randomized to the Prague-18 study (prasugrel vs.
Drug-eluting stents (DES) are the recommended stents for primary percutaneous coronary intervention (PCI). This study aimed to determine why interventional cardiologists used non-DES and how it influenced patient prognoses. The efficacy and safety outcomes of the different stents were also compared in patients treated with either prasugrel or ticagrelor.
View Article and Find Full Text PDFBackground: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease.
Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.